The estimated Net Worth of Anthony J. Polverino is at least $1.05 Milione dollars as of 31 August 2021. Dr Polverino owns over 4,900 units of Zymeworks BC Inc stock worth over $439,629 and over the last 7 years he sold ZYME stock worth over $0. In addition, he makes $606,708 as Chief Scientific Officer & Exec. VP of Early Devel. at Zymeworks BC Inc.
Sign up
Dr D ZYME stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Zymeworks BC Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,900 units of ZYME stock worth $73,500 on 31 August 2021.
The largest trade he's ever made was exercising 27,500 units of Zymeworks BC Inc stock on 12 December 2019 worth over $412,500. On average, Dr trades about 1,939 units every 35 days since 2018. As of 31 August 2021 he still owns at least 36,333 units of Zymeworks BC Inc stock.
You can see the complete history of Dr Polverino stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Anthony J. Polverino Ph.D. biography
Dr. Anthony J. Polverino Ph.D. is the Chief Scientific Officer & Exec. VP of Early Devel. at Zymeworks BC Inc.
What is the salary of Dr D?
As the Chief Scientific Officer & Exec. VP of Early Devel. of Zymeworks BC Inc, the total compensation of Dr D at Zymeworks BC Inc is $606,708. There are 1 executives at Zymeworks BC Inc getting paid more, with Dr. Ali Tehrani having the highest compensation of $877,656.
How old is Dr D?
Dr D is 58, he's been the Chief Scientific Officer & Exec. VP of Early Devel. of Zymeworks BC Inc since . There are 2 older and 4 younger executives at Zymeworks BC Inc. The oldest executive at Zymeworks BC Inc is Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D., 71, who is the VP of Intellectual Property.
What's Dr D's mailing address?
Anthony's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Insiders trading at Zymeworks BC Inc
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1 e Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
What does Zymeworks BC Inc do?
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
What does Zymeworks BC Inc's logo look like?
Complete history of Dr Polverino stock trades at Brainstorm Cell Therapeutics e Zymeworks BC Inc
Zymeworks BC Inc executives and stock owners
Zymeworks BC Inc executives and other stock owners filed with the SEC include:
-
Dr. Ali Tehrani,
Co-Founder, Pres, CEO & Director -
Dr. Anthony J. Polverino Ph.D.,
Chief Scientific Officer & Exec. VP of Early Devel. -
Neil A. Klompas C.A., CPA, CPA, CA,
Exec. VP of Bus. Operations & CFO -
Kathryn O'Driscoll,
Chief People Officer -
Wajida Leclerc,
VP of HR -
Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D.,
VP of Intellectual Property -
Dr. David Poon Ph.D.,
VP of Bus. Devel. and Alliance Management -
James Daniel Guylain Priour,
Chief Commercial Officer -
Dr. Neil Josephson M.D.,
Chief Medical Officer -
Daniel Dex,
VP of Legal & Corp. Sec. -
Neil Gallagher,
-
Jeffrey T L Smith,
EVP & Chief Medical Officer -
Kenneth Galbraith,
Chair & CEO -
James Priour,
Chief Commercial Officer -
Carlos Campoy,
-
Lilly & Co Eli,
10% owner -
Alessandra Cesano,
-
Ali Tehrani,
Chief Executive Officer -
David Kai Yuen Poon,
See Remarks -
Diana Hausman,
Chief Medical Officer -
Anthony J. Polverino,
Chief Scientific Officer -
Nick Bedford,
Director -
Natalie Sacks,
Director -
Kenneth J. Hillan,
-
Lota S. Zoth,
Director -
Leone D Patterson,
EVP, Chief Bus & Fin Officer -
Capital, Llc Eco R1,
10% owner -
Bros. Advisors Lp667, L.P.B...,
-
Paul Andrew Moore,
Chief Scientific Officer -
Christopher Astle,
SVP & Chief Financial Officer -
Neil A Klompas,
President & COO -
Neil Josephson,
Chief Medical Officer -
Group, Llc Green Jeremy Red...,
-
Nancy Davidson,
-
Susan Mahony,
-
Hollings Renton,
-
Derek John Michael Miller,
-
Troy Cox,
-
Kelvin Neu,